FULL REVASC - an RRCT on multivessel PCI in AMI
Ffr-gUidance for compLete non-cuLprit REVASCularization. A Registry Randomized Clinical Trial.
FULL REVASC randomised 1542 patients with STEMI or high-risk NSTEMI and multi-vessel disease, after primary PCI of the culprit lesion has been done. The treatment arms were
- ”Full revascularisation” with FFR-guided PCI of all vessels of at least 2,5 mm diameter. The PCI should be completed within the index admission.
- ”Initial conservative” with PCI of the culprit lesion only during index admission.
The updated combined primary endpoint was mortality, myocardial infarction or unplanned revascularization, as an event-driven study. Key secondary endpoint was mortality or myocardial infarction.
The patients were followed up by telephone interview after 30 days, one year and five years. Data from healthcare registries were used in countries where they were available.
The study included 32 PCI-centers in Sweden, Denmark, Serbia, Finland, Latvia, Australia and New Zealand. It was anticipated that the results would influence treatment guidelines globally.
The study database was locked on 16 Oct 2023. The main results will be published in the spring of 2024.